Trial Profile
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-426
- Sponsors Merck Sharp & Dohme Corp.
- 04 Mar 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2025.
- 01 Nov 2023 Results of final protocol-prespecified analysis, published in the European Urology
- 06 Jun 2023 Results of pooled exploratory analysis (n=2631 from four studies (KEYNOTE-426, JAVELIN Renal 100, CheckMate 9ER, CheckMate 214) assessing relationship of week 12 DepOR as a continuous variable with OS, hypothesizing not only complete but also deep partial responses might portend favorable longer-term survival in frontline advanced immuno-oncology renal cell carcinoma trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology